Drug Profile
Research programme: Ebola immunotherapeutics - Emergent BioSolutions
Alternative Names: Anti-Ebola monoclonal antibody - Emergent Biosciences; Ebola hyperimmune product - Emergent BioSciences; Modified vaccinia Ankara Ebola Zaire vaccine; MVA EBOZ; MVA-Ebola vaccine - Emergent BioSciencesLatest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Emergent BioSolutions
- Class Monoclonal antibodies; Viral vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA
- 20 Jul 2015 Emergent Biosolutions awarded BARDA for the development of Ebola monoclonal antibodies
- 06 Mar 2015 Preclinical trials in Ebola virus infections in USA before March 2015 (unspecified route)